PL374343A1 - Leczenie z wykorzystaniem cytokin - Google Patents
Leczenie z wykorzystaniem cytokinInfo
- Publication number
- PL374343A1 PL374343A1 PL03374343A PL37434303A PL374343A1 PL 374343 A1 PL374343 A1 PL 374343A1 PL 03374343 A PL03374343 A PL 03374343A PL 37434303 A PL37434303 A PL 37434303A PL 374343 A1 PL374343 A1 PL 374343A1
- Authority
- PL
- Poland
- Prior art keywords
- ata
- disease
- acc
- amyloid
- production
- Prior art date
Links
- 102000004127 Cytokines Human genes 0.000 title 1
- 108090000695 Cytokines Proteins 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 4
- 102000003814 Interleukin-10 Human genes 0.000 abstract 2
- 108090000174 Interleukin-10 Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229940076144 interleukin-10 Drugs 0.000 abstract 2
- 230000031261 interleukin-10 production Effects 0.000 abstract 2
- 101150037123 APOE gene Proteins 0.000 abstract 1
- 208000037259 Amyloid Plaque Diseases 0.000 abstract 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 abstract 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 abstract 1
- 206010061818 Disease progression Diseases 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 210000003710 cerebral cortex Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 230000005750 disease progression Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000008506 pathogenesis Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0212648.0A GB0212648D0 (en) | 2002-05-31 | 2002-05-31 | Treatment with cytokines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL374343A1 true PL374343A1 (pl) | 2005-10-17 |
| PL214984B1 PL214984B1 (pl) | 2013-10-31 |
Family
ID=9937825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL374343A PL214984B1 (pl) | 2002-05-31 | 2003-05-30 | Sposób okreslania obecnosci lub predyspozycji do choroby Alzheimera |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20050260767A1 (pl) |
| EP (1) | EP1509621B1 (pl) |
| JP (1) | JP4504186B2 (pl) |
| AT (1) | ATE442455T1 (pl) |
| AU (1) | AU2003273534A1 (pl) |
| CA (1) | CA2487734C (pl) |
| CY (1) | CY1110577T1 (pl) |
| DE (1) | DE60329179D1 (pl) |
| DK (1) | DK1509621T3 (pl) |
| ES (1) | ES2333312T3 (pl) |
| GB (1) | GB0212648D0 (pl) |
| PL (1) | PL214984B1 (pl) |
| PT (1) | PT1509621E (pl) |
| RU (2) | RU2337142C2 (pl) |
| SI (1) | SI1509621T1 (pl) |
| WO (1) | WO2003102237A1 (pl) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1335741A4 (en) * | 2000-08-25 | 2005-10-26 | Yeda Res & Dev | METHOD FOR THE PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDES (04.03.02) |
| WO2002026265A2 (en) | 2000-09-29 | 2002-04-04 | Schering Corporation | Pegylated interleukin-10 |
| US20070248955A1 (en) * | 2003-10-06 | 2007-10-25 | Novartis Ag | Use Of Genetic Polymorphisms To Predict Drug-Induced Hepatotoxicity |
| WO2005080594A2 (en) * | 2004-02-24 | 2005-09-01 | Innogenetics N.V. | Method for determining the risk of developing a neurological disease |
| GB0412859D0 (en) * | 2004-06-09 | 2004-07-14 | Immunoclin Ltd | Markers for atherosclerosis |
| WO2006110621A2 (en) * | 2005-04-11 | 2006-10-19 | Cornell Research Foundation, Inc. | Multiplexed biomarkers for monitoring the alzheimer's disease state of a subject |
| WO2006119170A2 (en) * | 2005-05-02 | 2006-11-09 | Avigen, Inc. | Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease |
| AU2007314501B2 (en) | 2006-09-28 | 2013-05-23 | Merck Sharp & Dohme Corp. | Use of pegylated IL-10 to treat cancer |
| RU2471487C2 (ru) * | 2007-02-06 | 2013-01-10 | Тай Джун ЙОО | Лечение и предупреждение нейродегенеративных заболеваний с использованием генной терапии |
| RU2549702C2 (ru) | 2008-12-17 | 2015-04-27 | Мерк Шарп И Доум Корп., | Получение и применение моно- и ди-пэг il-10 |
| ES2495266B8 (es) | 2013-02-13 | 2015-11-12 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer |
| CN106913865A (zh) | 2013-04-18 | 2017-07-04 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素‑10治疗疾病和病症的方法 |
| EP3010527B1 (en) | 2013-06-17 | 2018-08-08 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
| WO2014206899A1 (en) * | 2013-06-25 | 2014-12-31 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Boosting treg cells for treating alzheimer disease and related disorders |
| HUE042463T2 (hu) | 2013-07-18 | 2019-07-29 | Univ Colorado Regents | Készítmény gyulladásos ízületi betegség kezelésére |
| CN105658232A (zh) | 2013-08-30 | 2016-06-08 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素-10治疗疾病和病症的方法 |
| RU2016122957A (ru) | 2013-11-11 | 2017-12-19 | Армо Байосайенсиз, Инк. | Способы применения интерлейкина-10 для лечения заболеваний и расстройств |
| WO2015187295A2 (en) | 2014-06-02 | 2015-12-10 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
| AU2015333827A1 (en) | 2014-10-14 | 2017-04-20 | Armo Biosciences, Inc. | Interleukin-15 compositions and uses thereof |
| KR20170084033A (ko) | 2014-10-22 | 2017-07-19 | 아르모 바이오사이언시스 인코포레이티드 | 질환 및 장애를 치료하기 위해 인터루킨-10을 사용하는 방법 |
| WO2016126615A1 (en) | 2015-02-03 | 2016-08-11 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| WO2016191587A1 (en) | 2015-05-28 | 2016-12-01 | Armo Biosciences, Inc. | Pegylated interleukin-10 for use in treating cancer |
| WO2017035232A1 (en) | 2015-08-25 | 2017-03-02 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0760098A4 (en) * | 1994-06-09 | 1997-07-16 | Univ Bar Ilan | DIAGNOSIS OF THE PATHOLOGICAL PHASE OF ALZHEIMER'S DISEASE BASED ON CYONKIN SECRETIONS BY MONONUCLEAR CELLS |
| RU2176914C2 (ru) * | 1995-05-30 | 2001-12-20 | Эли Лилли Энд Компани | Способ лечения нарушения познавательной функции |
-
2002
- 2002-05-31 GB GBGB0212648.0A patent/GB0212648D0/en not_active Ceased
-
2003
- 2003-05-30 PT PT03740698T patent/PT1509621E/pt unknown
- 2003-05-30 AU AU2003273534A patent/AU2003273534A1/en not_active Abandoned
- 2003-05-30 AT AT03740698T patent/ATE442455T1/de active
- 2003-05-30 DE DE60329179T patent/DE60329179D1/de not_active Expired - Lifetime
- 2003-05-30 WO PCT/GB2003/002369 patent/WO2003102237A1/en active Application Filing
- 2003-05-30 JP JP2004510473A patent/JP4504186B2/ja not_active Expired - Fee Related
- 2003-05-30 SI SI200331708T patent/SI1509621T1/sl unknown
- 2003-05-30 DK DK03740698.0T patent/DK1509621T3/da active
- 2003-05-30 PL PL374343A patent/PL214984B1/pl unknown
- 2003-05-30 RU RU2004139089/13A patent/RU2337142C2/ru not_active IP Right Cessation
- 2003-05-30 US US10/516,421 patent/US20050260767A1/en not_active Abandoned
- 2003-05-30 EP EP03740698A patent/EP1509621B1/en not_active Expired - Lifetime
- 2003-05-30 CA CA2487734A patent/CA2487734C/en not_active Expired - Fee Related
- 2003-05-30 ES ES03740698T patent/ES2333312T3/es not_active Expired - Lifetime
-
2008
- 2008-04-28 RU RU2008116925/10A patent/RU2519651C2/ru not_active IP Right Cessation
-
2009
- 2009-12-09 CY CY20091101286T patent/CY1110577T1/el unknown
-
2012
- 2012-01-23 US US13/356,374 patent/US20120214866A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE442455T1 (de) | 2009-09-15 |
| ES2333312T3 (es) | 2010-02-19 |
| RU2008116925A (ru) | 2009-11-10 |
| EP1509621B1 (en) | 2009-09-09 |
| RU2004139089A (ru) | 2005-08-10 |
| CY1110577T1 (el) | 2015-04-29 |
| JP2005528119A (ja) | 2005-09-22 |
| GB0212648D0 (en) | 2002-07-10 |
| PT1509621E (pt) | 2009-12-17 |
| DK1509621T3 (da) | 2010-01-18 |
| US20050260767A1 (en) | 2005-11-24 |
| RU2519651C2 (ru) | 2014-06-20 |
| EP1509621A1 (en) | 2005-03-02 |
| JP4504186B2 (ja) | 2010-07-14 |
| DE60329179D1 (de) | 2009-10-22 |
| AU2003273534A1 (en) | 2003-12-19 |
| CA2487734C (en) | 2012-03-06 |
| SI1509621T1 (sl) | 2010-03-31 |
| PL214984B1 (pl) | 2013-10-31 |
| WO2003102237A1 (en) | 2003-12-11 |
| CA2487734A1 (en) | 2003-12-11 |
| RU2337142C2 (ru) | 2008-10-27 |
| US20120214866A1 (en) | 2012-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0212648D0 (en) | Treatment with cytokines | |
| Au et al. | Recent advances in the study of bipolar/rod-shaped microglia and their roles in neurodegeneration | |
| TW200507792A (en) | Treatment instrument for EMR, and EMR device | |
| NZ579050A (en) | Treatment and prevention of neurodegenerative diseases using gene therapy | |
| IL179751A0 (en) | Human autism predisposition gene encoding a transcription factor and uses thereof | |
| IL179831A0 (en) | Human autism susceptibility gene encoding prkcb1 and uses thereof | |
| DK1656458T3 (da) | Human autisme-susceptibilitetsgen og anvendelser deraf | |
| Wang et al. | A novel de novo mutation of ACTG1 in two sporadic non-syndromic hearing loss cases | |
| WO2004037852A3 (en) | Thymidylate synthase polymorphisms for use in screening for cancer susceptibility | |
| Kim et al. | Psychiatric characteristics according to tinnitus severity | |
| Kern et al. | Role of insulin in Alzheimer's disease: approaches emerging from basic animal research and neurocognitive studies in humans | |
| Marcon | APOLIPOPROTEIN E AND INFLAMMATORY CYTOKINES PROMOTER GENOTYPING IN A GROUP OF CENTENARIANS FROM THE “CaT: Centenari a Trieste” ONGOING STUDY | |
| Meybodian et al. | The screening of hearing and the common deafness gene in the elderly in Iran | |
| Matta et al. | Heads-It's Parkinson's; Tails-it's cancer, a kindred of Parkinsonism and Malignancies | |
| Rauf et al. | Expression profile of apoptotic genes BAK1 and BCL2 in Pakistani presbycusis patients from Faisalabad and Chichawatni populations | |
| Cipriani et al. | Cotard: The man and the syndrome | |
| Thampy et al. | The Role of Oxidative Stress and Cytokine Storm in the Pathogenesis, Oral Manifestation, Progression and Adverse Effects Related to SARS-Cov2 Infection-A Review. | |
| Gök et al. | Genomic analysis of the interleukin-1β-511 and interleukin-6-174 gene polymorphisms in Turkish patients with epilepsy | |
| Chacko et al. | Trinucleotide repeat analysis of spinocerebellar ataxia patients in Oman | |
| Li et al. | Clinical and genetic characteristics of a case of primary ciliary dyskinesia caused by new frameshift mutation of the DNAH5 gene | |
| Gaffney et al. | Bilateral acoustic neurofibromatosis camouflaged by corticosteroid treatment of sudden sensorineural hearing loss | |
| Gosavi et al. | A report of two cases of Guillian Barre syndrome variants post dengue infection | |
| Nada et al. | Role of Polymorphism (rs2986017) and (rs11191692) in the Calcium Homeostasis Modulator 1 (CALHM1) Gene in Temporal Lobe Epileps. | |
| Strandberg | Alzheimer's disease and angiogenesis | |
| TH114623B (th) | แบบแผนต่างๆของการรักษาโรคด้วยภูมิคุ้มกันที่ขึ้นอยู่กับสถานะของอะโปอี |